Company intelligence / Profile preview
RDP Pharma AG
Romanshorn, Thurgau, Switzerlandrdp-pharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
RDP Pharma AG is developing first-in-class small molecule drugs using its proprietary PROMPTDegrader™ platform to target intrinsically disordered regions in disease-relevant proteins. The company is focused on advancing programs toward clinical trials, but as of mid/late 2024, no clinical results have been disclosed.
- Therapeutic areas
- OncologyImmunologyOtherNeurologyInfectious Diseases
- Modalities
- Small molecules (targeted protein degraders)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical or biotech partnerships publicly announced as of May 2025.
Beyond the preview
Go deeper on RDP Pharma AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RDP Pharma AG.